Diabetic foot ulcers are a critical complication of diabetes, characterized by chronic wounds on the lower extremities. Resulting from a combination of neuropathy, poor circulation, and immune deficiencies, these ulcers are highly susceptible to infection, which can exacerbate their severity and lead to serious outcomes such as hospitalization and amputation. The psychological and physical impact on patients is immense, often requiring prolonged treatment and care.

Statistics:

• Affects 13% of diabetics annually in North America.
• Up to 25% of diabetic patients develop ulcers at some point.
• Global prevalence ranges from 6.3% to 10.5% among diabetic populations.
• DFUs are a leading cause of hospitalization and contribute significantly to healthcare costs, with annual expenses related to ulcers and amputations estimated between $9 billion to $13 billion in the U.S.

DeNovaMed’s Technological Approach: At DeNovaMed, we are dedicated to addressing the challenges of diabetic foot ulcers through the development of innovative treatments. Our novel compounds are designed to target and disrupt the bacterial infections commonly associated with DFUs, preventing the progression to severe infections. By employing advanced drug delivery systems, we ensure that our treatments are directly targeted at the ulcers, enhancing healing and reducing the risk of further complications. Our approach not only promotes the healing of ulcers but also addresses the underlying infections, providing a comprehensive solution to improve patient outcomes and reduce the burden of DFUs on healthcare systems.